Valent Wins FDA Clearance for Glaucoma Drug

Valeant subsidiary Bausch + Lomb secured FDA approval for its glaucoma drug Vyzulta.

The drug is a daily monotherapy indicated for reduction of intraocular pressure in patients with open-angle glaucoma or ocular hypertension.

Clinical studies have showed the drug makes a statistically significant difference in patients’ IOP, according to the company’s announcement.

The company hopes to make the drug available by the end of the year, according to Valeant chairman and CEO Joseph C. Papa.